Pathogen Inactivated Blood Components: Advancing from Theory to Practice
Although the safety of the blood supply has been dramatically improved over the past two decades, allogeneic blood components still carry infectious risks. This is in marked contrast to other therapeutic compounds such as small molecules or even recombinant biologics such as insulin or growth factors. Currently, prevention of transfusion-associated disease depends on a pre-donation interview of potential donors followed by laboratory testing of the donor’s blood for infectious pathogens prior to release of the donor’s blood. Serologic testing is performed to detect retroviruses such as the Human Immunodeficiency Virus (HIV) as well as a number of the hepatitis viruses such as hepatitis B. Serologic screening is not routinely done for parvo virus B 19, hepatitis A, E and G. Further, with one exception, no screening tests for bacteria or protozoa exist. Recently, the scope and sensitivity of donor screening for viral infection has expanded by the addition of specific nucleic acid amplification tests. The addition of these screening tests has greatly narrowed the “window period” in which a seronegative donor might still transmit a viral infection.
KeywordsFresh Freeze Plasma Baxter Healthcare Donor Screening Count Increment Fresh Freeze Plasma Transfusion
Unable to display preview. Download preview PDF.
- 1.Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP, Transfusion Medicine: First of Two Parts; N Engl J Med 1999; 340: 438–47.Google Scholar
- 6.AuBuchon JP, Birkmeyer JD, Busch M. Safety of the blood supply in the United States: opportunities and controversies. Ann Int Med 1997; 127: 90509.Google Scholar
- 8.Corten L, Wiesehahn GP, Smyers JM et al. Photochemical inactivation of hepatitis B (HBV) and Hepatitis C (HCV) viruses in human plasma as assessed in a chimpanzee infectivity model. Blood 2000;96:Supplement 1.Google Scholar
- 9.Grass JA, Wafa T, Reames A, et al. Prevention of transfusion-associated graft-versus-host disease by photochemical treatment. Blood 1999; 93: 314047.Google Scholar
- 12.deAlarcon P, Benjamin R, Shopnick M et al. An open-label trial of Fresh Frozen Plasma (FIT) treated by the HelinxTM single-unit photochemical pathogen inactivation system in patients with congenital coagulation factor deficiencies. Blood 2000;96 supplement 1: 254.Google Scholar
- 14.Moroff G, Sohmer PR, Button LN et al. Proposed standardization of methods for determining the 24-hour survival of stored red cells. Trans-fusion 1984; 24: 109–14.Google Scholar
- 17.Rios J, Hambleton J, Viele M, et al. HelinxTM treated RBC transfusions are well tolerated and show comparable recovery and survival to control RBCs. Transfusion. 2001;41:supplement 38s.Google Scholar